Progyny, Inc. (PGNY) stock
Close on Nov 11, 2026Market cap $2.80BP/E 33.5Yield –
Progyny, Inc. grew revenue 5.5% to $1.34B over the twelve months to Sep 30, 2026. Operating income rose 46.5% to $125.79M, moving the operating margin from 6.8% to 9.4%. Free cash flow was $179.64M, down 7.1% from a year earlier. At the latest close the market valued the company at $2.80B, 33.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $2.80B
- P/E ratio
- 33.5
- Price to sales
- 2.09
- Price to book
- 6.76
- Dividend yield
- –
- Free cash flow yield
- 6.41%
Fundamentals
- Revenue
- $1.34B
- Net income
- $91.02M
- EPS, diluted
- $1.09
- Free cash flow
- $179.64M
- Book value per share
- $5.10
- Diluted shares
- 81M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $36.43
- Open
- $36.41
- Day's range
- $35.93 – $36.52
- Volume
- 892,245
- Average volume (20 days)
- 1,076,077
- Index membership
- S&P SmallCap 600 (since Nov 2024), Russell 2000 (since Dec 2019), Russell 3000 (since Feb 2020)
- Beta (5 years)
- 1.06
- 52-week range
- $16.10 – $36.52
- RSI (14 days)
- 83.2
- Volatility (1 year)
- 50.3%
- Relative volume
- 0.79×
- WACC
- 10.2%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PGNY | S&P 500 | Difference | PGNY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +30.7% | -2.4% | +33.1 pts | ||
| 3 months | +37.4% | -1.2% | +38.5 pts | ||
| Year to date | +42.1% | +12.3% | +29.8 pts | ||
| 1 year | +53.3% | +12.4% | +40.9 pts | ||
| 3 years | +20.9% | +78.8% | −57.9 pts | +6.5% | +21.4% |
| 5 years | -40.1% | +75.2% | −115.2 pts | -9.7% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Progyny filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Progyny
Services-Misc Health & Allied Services, NEC
Progyny provides specialized healthcare benefits management focused on fertility, family building, and women's health. The company offers employers customized benefits packages based on bundled treatment cycles that encompass clinical care, diagnostic testing, and advanced procedures. Its portfolio includes pharmacy benefit services for treatment-related medications, care navigation, and support programs spanning pregnancy, postpartum care, menopause, and parent wellbeing. Progyny primarily serves large employers across numerous private and public industries, contracting directly with organizations to manage comprehensive benefits for their workforces and dependents.
Company profile, executives and historyProgyny stock: common questions
What is Progyny's stock price?
PGNY closed at $36.50 on Nov 11, 2026, up 0.19% on the day. Over the past 52 weeks it traded between $16.10 and $36.52.
What is Progyny's market cap?
Progyny was worth $2.80B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PGNY's P/E ratio?
PGNY trades at 33.5 times earnings, based on diluted earnings per share of $1.09 over the twelve months to Sep 30, 2026.
How much revenue does Progyny make?
Progyny reported revenue of $1.34B for the twelve months to Sep 30, 2026, up 5.5% from a year earlier.
Does Progyny pay a dividend?
No. Progyny has not paid a cash dividend over the last twelve months.
When does Progyny report earnings next?
Progyny is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PGNY stock performed over the past year?
Including dividends, PGNY returned +53.3% over the past year, against +12.4% for the S&P 500.
How many PGNY shares are sold short?
5M shares were sold short at the latest FINRA report, 6.37% of the float, or 6.3 days of average trading volume.
Who are Progyny's competitors?
Companies most similar to Progyny by business, industry and size include SHC, CON, AGL, VMD, DVA.
See a number that looks wrong?